Compare DCBO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | CRMD |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Canada | United States |
| Employees | 900 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.3M | 590.7M |
| IPO Year | 2020 | 2009 |
| Metric | DCBO | CRMD |
|---|---|---|
| Price | $22.88 | $7.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $32.00 | $14.83 |
| AVG Volume (30 Days) | 39.4K | ★ 759.2K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $12.89 | $0.30 |
| Revenue Next Year | $11.44 | N/A |
| P/E Ratio | $22.04 | ★ $10.79 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $14.39 | $6.13 |
| 52 Week High | $28.72 | $13.02 |
| Indicator | DCBO | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 47.85 |
| Support Level | $21.72 | $7.09 |
| Resistance Level | $23.67 | $9.01 |
| Average True Range (ATR) | 0.77 | 0.23 |
| MACD | -0.34 | -0.03 |
| Stochastic Oscillator | 17.25 | 32.10 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.